Avenue Therapeutics
menu
  • About
    • Management Team
    • Board of Directors
  • Pipeline
    • BAER-101
    • IV Tramadol
    • AJ201
  • Publications
  • Investors
    • News & Events
      • Overview
      • Press Releases
      • IR Calendar
      • Email Alerts
    • Company Info
      • Overview
      • Management Team
      • Presentations
      • Contacts
      • FAQ
    • Financial Info
      • Overview
      • Financial Results
      • Income Statement
      • Balance Sheet
      • Cash Flow
      • Analyst Coverage
    • Stock Data
      • Quote
      • Charts
      • Historical Data
    • SEC Filings
      • Overview
      • All SEC Filings
      • Annual Reports
      • Quarterly Reports
      • Section 16 Filings
    • Governance
      • Overview
      • Board of Directors
      • Board Committees
      • Governance Documents
  • Events
  • Contact Us
    • Careers
      • Email Alerts

Press Releases

Investors

Investors

  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Analyst Coverage
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Nov 02, 2023

Avenue Therapeutics Announces Closing of $5.0 Million Public Offering

Oct 31, 2023

Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering

Sep 05, 2023

Avenue Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference

Aug 10, 2023

Avenue Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

Aug 01, 2023

Avenue Therapeutics Announces High Potency and Full Efficacy in a Model of Generalized Seizures for its Novel GABA-A Receptor Potentiator, BAER-101, Supporting Phase 2 Clinical Study

Jul 27, 2023

Avenue Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)

Jul 25, 2023

Avenue Therapeutics Announces Agreement with the FDA on the Study Design and Analysis Approach of the Phase 3 Safety Study for IV Tramadol

May 12, 2023

Avenue Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

Apr 27, 2023

Avenue Therapeutics to Present at Aegis Capital Virtual Conference

Apr 17, 2023

Avenue Therapeutics Announces Regulatory Update Based on Type C Meeting with FDA and Next Steps in the Development of IV Tramadol

  • arrow_back
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • arrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
  • Privacy
  • Disclaimer
  • Contact Us


twitter icon linked-in icon
Website Design, Maintenance and Hosting by Tidal Media Group
Copyright ©2025 Avenue Therapeutics.

logo